CD81 is a cell surface protein which belongs to the tetraspanin family. While in multiple myeloma its expression on plasma cells is associated with worse prognosis, this has not yet been explored in acute myeloid leukemia (AML). We measured membrane expression of CD81 on AML cells at diagnosis, evaluated its association with AML characteristics and its influence on patient outcome after intensive chemotherapy in a cohort of 134 patients. CD81 was detected in 92/134 (69%) patients. Patients with AML expressing CD81 had elevated leukocyte count (P=0.02) and were more likely classified as intermediate or adverse-risk by cytogenetics (P<0.001). CD81 expression had a negative impact on survival (event-free survival, overall survival and relapse-free survival) in univariate (P<0.001) and in multivariate analyses (P=0.003, 0.002 and <0.001, respectively). CD81 has a negative impact on OS in patients with NPM1 mutation (P=0.01) and in patients ELN-favorable (P=0.002). In conclusion, this cell surface marker may be a new prognostic marker for diagnostic risk classification and a potential therapeutic target for drug development in AML.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308734PMC
http://dx.doi.org/10.18632/oncotarget.11481DOI Listing

Publication Analysis

Top Keywords

acute myeloid
8
myeloid leukemia
8
tetraspanin cd81
4
cd81 adverse
4
adverse prognostic
4
prognostic marker
4
marker acute
4
cd81
4
leukemia cd81
4
cd81 cell
4

Similar Publications

Construction of a stromal-related prognostic model in acute myeloid leukemia by comprehensive bioinformatics analysis.

Curr Res Transl Med

January 2025

Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:

Background: Stromal cells play a pivotal role in the tumor microenvironment (TME), significantly impacting the progression of acute myeloid leukemia (AML). This study sought to develop a stromal-related prognostic model for AML, aiming to uncover novel prognostic markers and therapeutic targets.

Methods: RNA expression data and clinical profiles of AML patients were retrieved from the Cancer Genome Atlas (TCGA).

View Article and Find Full Text PDF

Cell type-specific upregulation of NKG2D ligand MICA in response to APTO253.

Ann Transl Med

December 2024

Institute for Tumor Immunology, Center for Tumor Biology and Immunology, Philipps-University Marburg, Marburg, Germany.

One of the most important targets for natural killer (NK) cell-mediated therapy is the induction of natural killer group 2D ligand (NKG2D-L) expression. APTO253 is a small molecule that selectively kills acute myeloid leukemia (AML) cells, and it has been reported that APTO253 can induce Krüppel-like factor 4 (KLF4) expression and downregulate c-MYC expression. Recently, we discovered a novel role of APTO253 in modulating the NK cell response by inducing surface expression of NKG2D-Ls, especially MHC class I polypeptide-related sequence A (MICA), in AML cells.

View Article and Find Full Text PDF

Whilst severe liver dysfunction is rarely encountered at the time of diagnosis for patients with acute myeloid leukemia (AML), mild elevations aminotransferase (<5 times the upper limit of normal) may be more frequently seen. Liver dysfunction at the time of diagnosis of AML is a parameter that requires investigation and can assist the clinicians in predicting prognosis. The aim of the present study was to investigate liver dysfunction at the time of diagnosis using the assoicated parameters in patients with AML.

View Article and Find Full Text PDF

Acute myeloid leukaemia (AML) is a haematologic malignancy with high relapse rates in both adults and children. Leukaemic stem cells (LSCs) are central to leukaemopoiesis, treatment response and relapse and frequently associated with measurable residual disease (MRD). However, the dynamics of LSCs within the AML microenvironment is not fully understood.

View Article and Find Full Text PDF

The chronic myeloid leukemia (CML) is easily diagnosed by laboratory examination, however, rare BCR-ABL1 mRNA transcripts variants, such as e1a3 present diagnosis and therapeutic challenges. This case report details the diagnosis and management of a CML patient with the e1a3 transcript by FISH and RT-PCR. Following initial diagnosis, the patient was treated with the tyrosine kinase inhibitor (TKI) Flumatinib.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!